BeatIt-MV Therapy for Minimally Verbal Autistic Adults
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new program called BeatIt-MV (also known as BeatIt-2 or Behavioral Activation Intervention) to assist autistic adults who speak very little and experience depression. The goal is to determine if this program can improve their mood and daily life. Participants will attend 12 weekly sessions with a support person. This trial suits adults living in or near New Jersey or New York who have difficulty speaking, have been diagnosed with autism and depression, and have someone to assist them during the sessions. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance support for autistic adults.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be currently receiving other treatment for depression.
What prior data suggests that the BeatIt-MV intervention is safe for minimally verbal autistic individuals?
Research has shown that therapies like BeatIt-MV, which aim to increase activity to improve mood, are generally safe. Although specific safety data for BeatIt-MV is not yet available, similar treatments have been well-received and typically do not cause harmful effects. This trial is in an early stage, focusing on the treatment's practicality, but the positive safety record of similar therapies is encouraging. Participants can feel reassured by the safety of these types of interventions.12345
Why are researchers excited about this trial?
BeatIt-MV is unique because it focuses on enhancing communication skills in minimally verbal autistic adults through a series of personalized, interactive sessions. Unlike typical approaches that may rely on medication or general behavioral therapies, BeatIt-MV involves direct engagement with both participants and their support persons in weekly sessions designed to foster meaningful communication. Researchers are excited about this treatment because it offers a hands-on, supportive framework that could lead to more effective communication improvements, potentially enhancing the quality of life for participants and their families.
What evidence suggests that the BeatIt-MV treatment might be effective for minimally verbal autistic adults?
Research shows that the BeatIt-MV therapy, a version of the BeatIt-2 program, may help autistic adults who speak very little. This trial will specifically evaluate the BeatIt-MV intervention. Studies on similar programs, like BeatIt-Aut, suggest that this type of therapy is practical and well-received by autistic adults with low mood. Although strong evidence is still being gathered on its effectiveness, the therapy encourages participation in positive activities, which has reduced depression symptoms. Early signs suggest that these interventions could improve mood and participation in this group, offering hope for the positive impact of BeatIt-MV therapy.12356
Who Is on the Research Team?
Vanessa Bal, PhD
Principal Investigator
Rutgers University - New Brunswick
Are You a Good Fit for This Trial?
This trial is for minimally verbal adults over 18 with Autism Spectrum Disorder and depression, who have a support person and can travel to Rutgers University in New Jersey or New York. It's not suitable for those without these specific conditions or support.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention Development
Adapting the BeatIt-2 manual to consider specific needs of minimally verbal autistic adults
Treatment
Participants, along with support persons, will complete 12 weekly sessions of the BeatIt-MV intervention
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BeatIt-MV
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor